TABLE 1.
Characteristics of 175 patients hospitalized with COVID‐19 stratified according to the patients’ status of disease progression
| All patients (n = 175) | Disease progression group (n = 103) | Disease improved group (n = 72) | P‐value | |
|---|---|---|---|---|
| Age, median (IQR), y | 57 (42, 69) | 60 (40, 72) | 56 (29, 73) | .019 |
| Male | 106 (60.6) | 63 (61.2) | 43 (59.7) | .848 |
| Age, y | ||||
| ≥65 | 65 | 47 (72.3) | 18 (27.7) | .005 |
| <65 | 110 | 56 (50.9) | 54 (49.1) | |
| Comorbidities | ||||
| Hypertension | 52 (29.7) | 34 (33.0) | 18 (25.0) | .736 |
| Cardiovascular/Cerebrovascular diseases | 24 (13.7) | 19 (18.4) | 5 (6.9) | .030 |
| Diabetes | 19 (10.9) | 12 (11.7) | 7 (9.7) | .687 |
| Malignancy | 7 (4.0) | 5 (4.9) | 2 (2.8) | .490 |
| COPD | 4 (2.3) | 2 (1.9) | 2 (2.8) | .716 |
| Chronic kidney diseases | 10 (5.7) | 9 (8.7) | 1 (1.4) | .039 |
| Chronic liver diseases | 9 (5.1) | 4 (3.9) | 5 (6.9) | .367 |
| Main laboratory findings on admission | ||||
| Leukocytosis | 10 (5.7) | 7 (6.8) | 3 (4.1) | .461 |
| Leukocytopenia | 56 (32.0) | 41 (39.8) | 15 (20.8) | .008 |
| Lymphocytopenia | 60 (34.3) | 38 (36.9) | 22 (30.6) | .385 |
| Haemoglobin, g/L | 129 (106‐153) | 129 (109‐156) | 130 (106‐152) | .653 |
| Platelets, 109/L | 151 (108‐233) | 152 (107‐231) | 148 (110‐240) | .169 |
| Creatinine, µmol/L | 76.5 (55.8‐108.8) | 84.8 (54.2‐112.3) | 65.2 (56.2‐98.6) | .001 |
| Troponin, pg/mL | 14.6 (6.6‐16.9) | 18.3 (7.8‐26.2) | 7.8 (4.2‐10.2) | .001 |
| Alanine aminotransferase, U/L | 76 (24‐87) | 85 (26‐95) | 66 (20‐83) | .319 |
| Lactate dehydrogenase, U/L | 285 (198‐332) | 306 (204‐356) | 195 (168‐279) | .026 |
| CRP, mg/L | 68.0 (42.3‐92.1) | 82.3 (56.6‐102.3) | 57.7 (40.9‐96.6) | .022 |
| PCT, ng/mL | 4.20 (0.63‐2.69) | 6.08(2.01‐7.50) | 0.75 (0.44‐1.32) | .000 |
| ESR, mm/h | 26 (14‐30) | 32 (18‐41) | 24 (12‐39) | .034 |
| PT, s | 28.6 (15.6‐22.4) | 32.6 (23.1‐36.8) | 25.2 (12.3‐20.6) | .030 |
| D‐dimer, ng/mL | 1104 (652‐1630) | 1516 (852‐2630) | 758 (361‐897) | .023 |
| CD4, /µL | 581 (436‐622) | 652 (462‐784) | 466 (369‐605) | .001 |
| IL‐6, pg/mL | 163 (39‐255) | 253 (42‐302) | 78 (33‐102) | .000 |
| Use of Oseltamivir | 96 (54.8) | 54 (52.4) | 42 (58.3) | .440 |
| Use of Arbidol Hydrochloride | 169 (96.6) | 98 (95.1) | 71 (98.6) | .215 |
| Use of Lopinavir/Ritonavir or Darunavirand/Cobicistat | 90 (51.4) | 52 (50.5) | 38 (52.8) | .765 |